Mixed subtype thyroid cancer: A surveillance, epidemiology, and end results database analysis

Abstract

The prognosis of patients with mixed subtype thyroid cancer (MSTC) is unclear. The present study compared the prognoses of MSTC, papillary thyroid cancer (PTC), and follicular thyroid cancer (FTC) to provide a new perspective regarding the treatment guidelines for these diseases. We evaluated data from patients with thyroid cancer who were included in the Surveillance, Epidemiology, and End Results database between 2004 and 2013. Patient mortality was evaluated using Cox proportional hazards regression analyses and Kaplan-Meier analyses with log-rank tests. The univariate Cox regression analysis showed that the cancer-specific survival rate for MSTC was lower than that for PTC and FTC. However, in the multivariate Cox regression analysis, the cancer-specific survival rate for MSTC was similar to that for PTC and FTC. Before matching influence factors, the cancer-specific survival rate for MSTC was lower than that for PTC and FTC. However, after propensity score matching for relevant factors, the cancer-specific survival rate for MSTC was also similar to that for PTC and FTC. Our result would be beneficial and provide a guideline for the understanding of MSTC.

Survival and Analysis for Mixed Medullary-Follicular Thyroid Carcinoma: based on SEER database

“…First, the extremely low incidence rate has led to a vague understanding of MMFTC. From 2000 to 2016, there were about 100000 cases of thyroid cancer (14), of which, MMFTC were only diagnosed in 203 cases (0.2%), which was consistent with those previously reported by Papotti et al (15) and Kashima et al (16). In addition, the unique pathological characteristics impede the diagnosis, leading to more signi cant prognostic difference.…”

Iodine Status in the Colombian Population and the Impact of Universal Salt Iodization: A Double-Edged Sword?

“…Whilst it is not possible to establish a definite “cause-effect” association between the intake of iodine and thyroid cancer, the growing use of diagnostic methods must also be taken into account (ultrasound, CT, and MRI) as well as the indiscriminate use of fine needle aspiration, which have contributed to increased detection of thyroid cancer. For example, in the United States of America, between the years 1975 and 2009, the incidence of this type of cancer rose from 4.9 to 14.3 per 100,000 inhabitants, while the rate of mortality remained constant (from 0.56 to 0.52 per 100,000, respectively) [21, 22]. Such disease-based screening has contributed to “overdiagnosis” and potential “overtreatment,” accounting for the increase in the frequency of thyroid cancer over the last few decades (rather than to the implementation of USI programs).…”

Adrenal metastasis as the initial diagnosis of synchronous papillary and follicular thyroid cancer

“…Our patient was ultimately diagnosed with FTC of the right lobe, NIFTP of the left lobe, and papillary microcarcinoma of the left lobe. While not as exceptional as reports of concurrent presentation of DTC with medullary or anaplastic thyroid carcinoma [ 23 – 25 ], the presence of multiple subtypes of thyroid carcinoma in the same patient is rare [ 3 ]. The simultaneous occurrence of both follicular and papillary neoplasms can be attributed to their common cellular origin from follicular epithelial thyroid cells involved in iodine metabolism [ 26 ].…”

“…Differentiated thyroid carcinomas (DTC) account for the vast majority of all thyroid cancer cases, of which roughly 80% are papillary thyroid carcinoma (PTC) and 10–15% are follicular thyroid carcinoma (FTC) [ 2 ],medullary and anaplastic thyroid cancer make up the remaining 5% of cases. The concurrent presentation of multiple histologic types of thyroid cancer in the same patient is rare, accounting for approximately 0.06% of thyroid cancers in database analyses [ 3 ]. Amongst DTC, prognosis is excellent for most patients, even for the 20–50% of cases that present with local metastases [ 4 ].…”